NEW
Sybrava

Sybrava

inclisiran

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Inclisiran
Indications/Uses
Adults w/ primary hypercholesterolaemia (heterozygous familial & non-familial) or mixed dyslipidaemia, as adjunct to diet in combination w/ statin or statin w/ other lipid-lowering therapies in patients unable to reach LDL-C goals w/ max tolerated statin dose; or alone or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant or for whom statin is contraindicated.
Dosage/Direction for Use
Initially 1 single SC inj, again at 3 mth, followed by every 6 mth.
Contraindications
Special Precautions
Not to be inj into areas of active skin disease or injury eg, sunburns, inflammation, skin rashes &/or infections. Haemodialysis patients. Severe hepatic (Child-Pugh class C) & renal impairment. Avoid use during pregnancy. Lactation. Childn <18 yr.
Adverse Reactions
Inj site reactions eg, pain, erythema, rash.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AX16 - inclisiran ; Belongs to the class of other lipid modifying agents.
Presentation/Packing
Form
Sybrava soln for inj (pre-filled syringe) 284 mg/1.5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in